Low-dose oral minoxidil (LDOM) and topical minoxidil: consensus recommendations for managing male and female pattern Hair loss in Hair transplant patients using a modified delphi process - PubMed
2 hours ago
- #hair transplant
- #hair loss
- #minoxidil
- Low-dose oral minoxidil (LDOM) and topical minoxidil lack standardized guidelines for managing male and female pattern hair loss (MPHL and FPHL) in hair transplant patients.
- An international panel of hair transplant surgeons used a modified Delphi process to develop consensus recommendations.
- Key recommendations include checking body weight and blood pressure before starting LDOM, with individualized testing as needed.
- Recommended starting doses: 1.25-2.5 mg/day for MPHL and 0.625-1.25 mg/day for FPHL, with maximum doses of 5 mg and 2.5 mg, respectively.
- Clinical response to LDOM is expected within 4-6 months, and therapy can be continued long-term if effective and well-tolerated.
- Post-hair transplant, LDOM can typically be resumed 1-3 days after the procedure.
- Topical minoxidil can be applied to the grafted area 7-14 days post-transplant, with 5% concentration effective for frontal scalp and vertex.
- Minoxidil should be avoided during pregnancy and breastfeeding.
- The study provides a treatment algorithm for integrating LDOM and topical minoxidil in hair-transplant patients with pattern hair loss.